<DOC>
	<DOC>NCT00586846</DOC>
	<brief_summary>This study is designed to test the safety and feasibility of the simultaneous administration of a biphosphonate with chemotherapy for the treatment of osteosarcoma in newly diagnosed patients.</brief_summary>
	<brief_title>Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Newly diagnosed, previously untreated biopsy proven highgrade osteosarcoma. Patient who have undergone a definitive surgical resection as their primary surgery are still eligible for participation in this study. No prior chemotherapy or radiation therapy Adequate renal function: creatinine &lt; or = to 1.5 upper limit of normal Adequate liver function as defined by bilirubin &lt; or = to 1.5 X upper limit of normal and AST &lt; or = to 3 X upper limit of normal institutional range Adequate hematopoietic function as defined by platelet count &gt; or = to 100,000/ram3 an absolute neutrophil count &gt; or = to 1,000/mm3. Adequate cardiac function as defined by shortening fraction &gt; or = to 28% by echocardiogram OR ejection fraction &gt; or = to 50% by radionuclide angiogram Performance status &lt; or = to 2 Prior history of cancer Prior treatment for cancer Prior history of Paget's disease Prior history of pericarditis, myocarditis, symptomatic arrhythmia or symptomatic cardiac conduction abnormalities Pregnancy or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cisplatin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>03-074</keyword>
</DOC>